Google is one step closer to establishing its artificial intelligence model in 1000 languages.

When Microsoft and Google try their best for whose artificial intelligence chat robot is better, we can easily find that this is not the only purpose of machine learning and language model. In addition to the rumored plan to showcase more than 20 products driven by artificial intelligence in this year’s annual Google I/O event, Google is moving towards the goal of establishing an artificial intelligence language model that supports 1000 different languages.

In the update released on Monday, Google shared more information about the Universal Speech Model (USM), which Google called a "critical first step" to achieve its goal.

YouTube has used USM to generate closed captions, and it also supports Automatic Speech Recognition (ASR), which can automatically detect and translate languages, including English, Mandarin Chinese, Amharic, Cebu, Assam and so on.

Now, Google USM supports more than 100 languages, and will be used as a "foundation" to build a wider system. At the same time, Meta is developing a similar artificial intelligence translation tool, but it is still in its early stage.

You can read more about USM and how it works in research papers published by Google:

One goal of this technology may be to detect and provide real-time translation in augmented reality glasses, just like the concept demonstrated by Google in I/O activities last year. However, this technology seems to be a little far away, and Google’s wrong expression of Arabic during the I/O conference proves how easy it is to make mistakes.

Nature writes: In the next 30 years, cancer will cost the world 25 trillion US dollars.

Monoclonal antibody against B-cell psoriasis leukemia, a target of cancer artificial intelligence

①Nature:Cancer will cost the world $25 trillion over next 30 years

In the next 30 years, cancer may cost the world $25 trillion.

DOI :10.1038/d41586-023-00634-9

②Seminars in Cancer Biology:Artificial intelligence in cancer immunotherapy: applications in neoantigen recognition, antibody design and immunotherapy response prediction

Review: Application and development of artificial intelligence in the field of precision oncology: new antigen recognition, antibody design and immunotherapy response prediction.

DOI :10.1016/j.semcancer.2023.02.007

③Molecular Cancer:CD39/CD73/A2AR pathway and cancer immunotherapy

Review: New progress in pathophysiological function of CD39/CD73/A2AR pathway in cancer development, metastasis and drug resistance.

DOI :10.1186/s12943-023-01733-x

④Immunity:B cell receptor signaling in germinal centers prolongs survival and primes B cells for selection

B cell receptor signal transduction in germinal center prolongs the survival of B cells and initiates the selection of B cells.

DOI :10.1016/j.immuni.2023.02.003

⑤Frontiers in Immunology:Metabolic rewiring in keratinocytes by miR-31-5p identifies therapeutic intervention for psoriasis

The metabolic recombination of miR-31-5p in keratinocytes determines the intervention on psoriasis.

DOI :10.15252/emmm.202215674

⑥Journal of Hematology & Oncology:Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting

The latest drug research and new scheme progress of American Society of Hematology (ASH) for acute myeloid leukemia (AML)
DOI :10.1186/s13045-023-01411-x

⑦FDA extended the review of adult Roctavian with severe hemophilia A because of "significant changes in a large number of additional data"

⑧ A small molecule MET inhibitor, gumetinib, which was developed by Shanghai Institute of Pharmacology, China Academy of Sciences, was approved for marketing, and it was used for locally advanced or metastatic non-small cell lung cancer (NSCLC) with the jump mutation (METex14 jump) in exon 14 of mesenchymal-epithelial transforming factor (MET).

⑨ The clinical study of Relma-cel targeting CD19 for first-line high-risk large B-cell lymphoma was officially launched.

⑩ Lilly will terminate the research and development of Solanezumab for Alzheimer’s disease because it fails to slow down the cognitive decline of preclinical Alzheimer’s patients.

The world of scientific exploration is full of challenges. AtaGenix pays tribute to every pioneer and is more committed to becoming your trusted partner!